Exacerbations requiring oral corticosteroids ‐ School‐age children · School‐aged children and adults
Intermittent ICS showed no clear difference in exacerbations requiring oral corticosteroids ‐ School‐age children compared with placebo (low certainty).
1 finding from 1 review
Exacerbations requiring oral corticosteroids ‐ adults · School‐aged children and adults
Intermittent ICS showed no clear difference in exacerbations requiring oral corticosteroids ‐ adults compared with placebo (low certainty).
1 finding from 1 review
Mean exacerbations requiring a course of oral corticosteroids · Preschool children (<6 years)
Intermittent ICS probably leads to lower exacerbations requiring oral corticosteroids compared with placebo (moderate certainty).
1 finding from 1 review
Exacerbations (OCS) · adults with asthma not well controlled on ICS
LAMA add‐on leads to lower exacerbations requiring oral corticosteroids (OCS) compared with ICS alone (high certainty).
1 finding from 1 review
Other oral symptoms (dysgeusia, dysphagia) · Patients with radiation-induced salivary gland dysfunction
1 finding from 1 review
Femoral neck bone mineral density (FN-BMD) · Older or community-dwelling adults
Meta-analysis of randomised trials of vitamin D supplementation for Bone mineral density in femoral neck, Community-dwelling adults: WMD 1.10 (95% CI 0.40 to 1.90), statistically significant. Umbrella review outcome-level evidence grade: Suggestive.
1 finding from 1 review
WMD 1.10 [0.40, 1.90]
8 studies
GRADE not reported
Femoral neck bone mineral density (FN-BMD) · patients with osteoporosis
1 finding from 1 review
BMD of femoral neck (Shengu capsule versus no intervention) · patients with osteoporosis
1 finding from 1 review
Femoral neck bone mineral density (FN-BMD) · patients with osteoporosis
1 finding from 1 review
Maintenance of clinical remission · Participants with Crohn's disease in remission
Methotrexate showed no clear difference in proportion of patients maintaining clinical remission (low dose oral… compared with placebo (low certainty).
1 finding from 1 review
Number of participants with worsening scores in corporal atrophy · people with pre‐malignant lesions
Proton pump inhibitor showed no clear difference in number of participants with worsening scores in corporal atrophy compared with control (low certainty).
1 finding from 1 review
Number of participants with worsening scores in corporal intestinal metaplasia · people with pre‐malignant lesions
Proton pump inhibitor showed no clear difference in number of participants with worsening scores in corporal intestinal… compared with control (low certainty).
1 finding from 1 review
Intervention not reported
Asthma exacerbation as defined by hospital admission or treatment with a course of oral corticosteroids · participants with asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Asthma exacerbation as defined by hospital admission or treatment with a course of oral corticosteroids · participants with exercise‐induced asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Oral health assessment · Adults with dry mouth due to radiotherapy (head and neck cancer) or Sjogren's Syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Oral health assessment · Adults with dry mouth due to Sjogren's Syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Adverse effects / specific side effects (oral allergic reactions, mucosal irritation, adverse symptoms such as nausea, gagging, vomiting) · Children and adolescents aged 16 years or less
1 finding from 1 review
Intervention not reported
Length of stay (days) ‐ oral anticoagulants · saving healthcare resources
1 finding from 1 review
Intervention not reported
Oral anticoagulants: time in target INR range (%) · patients with leading physiological parameters within therapeutic range
1 finding from 1 review
Intervention not reported
Time to achieve therapeutic range ‐ oral anticoagulants: time to achieve therapeutic prothrombin ratio (days) · patients with reducing time to achieve therapeutic control
1 finding from 1 review